Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

BACKGROUND: High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Glutsch, Valerie, Grän, Franziska, Weber, Judith, Gesierich, Anja, Goebeler, Matthias, Schilling, Bastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626404/
https://www.ncbi.nlm.nih.gov/pubmed/31300044
http://dx.doi.org/10.1186/s40425-019-0655-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626404/
https://www.ncbi.nlm.nih.gov/pubmed/31300044
http://dx.doi.org/10.1186/s40425-019-0655-4

Ejemplares similares